CLAIMS

1. Use of an anti-C5 agent in the manufacture of a medicament for the treatment, stabilization and/or prevention of Stargardt disease, wherein the anti-C5 agent is a pegylated or unpegylated aptamer that binds to C5 complement and has a sequence of SEQ ID NO: 4 or SEQ ID NO: 67.

2. The use of claim 1 wherein the anti-C5 agent is to be administered by ocular administration, intravitreal administration, or peri-ocular administration.

3. The use of claim 1 wherein the anti-C5 agent is comprised in a depot formulation.

4. The use of any of claim 1 wherein the anti-C5 agent has the following structure:



where ~~~ indicates a linker, and

Aptamer =

fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfU fUAfCfCfUmGfCmG-3T (SEQ ID NO: 4), wherein fC and fU = 2′ fluoro nucleotides, mG and mA = 2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine.

5. The use of claim 4 wherein the linker is an alkyl linker.

6. The use of claim 5 wherein the alkyl linker comprises 2 to l8 consecutive CH_2.

7. The use of any of claim 1 wherein the anti-C5 agent has the following structure:



or a salt thereof,

where Aptamer =

fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfU fUAfCfCfUmGfCmG-3T (SEQ ID NO: 4), wherein fC and fU = 2′ fluoro nucleotides,

mG and mA = 2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine.